CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer
BackgroundThe treatment of local–regional recurrent breast cancer (BC) after external beam radiotherapy is challenging. We aim to evaluate the effectiveness and safety of computed tomography (CT)–guided percutaneous iodine-125 brachytherapy for local recurrent BC.MethodsWe retrospectively analyzed 1...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1171813/full |
| _version_ | 1797741296292462592 |
|---|---|
| author | Juan Wang Xiaojing Chang Ke Xu Yansong Liang Jinxin Zhao Zezhou Liu Hongtao Zhang |
| author_facet | Juan Wang Xiaojing Chang Ke Xu Yansong Liang Jinxin Zhao Zezhou Liu Hongtao Zhang |
| author_sort | Juan Wang |
| collection | DOAJ |
| description | BackgroundThe treatment of local–regional recurrent breast cancer (BC) after external beam radiotherapy is challenging. We aim to evaluate the effectiveness and safety of computed tomography (CT)–guided percutaneous iodine-125 brachytherapy for local recurrent BC.MethodsWe retrospectively analyzed 15 patients with local recurrent BC treated with CT-guided interstitial implantation of iodine-125 seeds. Regular contrast-enhanced CT was conducted to evaluate the tumor response. Follow-up survival, quality of life, and adverse events were analyzed.ResultsAmong the 15 patients, five were elderly patients (older than 80 years) and six were complicated with chronic underlying diseases. The median number of 125I seeds implantation was 33 (range: 20–130) with median dose 90 (D90, the minimum dose covering 90% of the target volume) of 108 Gy (range: 60–120 Gy). There was no significant difference in D90, V100 (the volume of the target receiving 100% of the prescription dose), and V150 (the volume of the target receiving 150% of the prescription dose) before and after operation (p > 0.05). The median follow-up was 14 months (range: 6–18 months). Six months after operation, the ORR was 66.7% (10/15) and the LCR was 93.3% (14/15). The 6- and 12-month survival rates were 100 and 41.6%, respectively, and the median survival time was 12.5 months. PS score decreased from 1.53 ± 0.81 to 0.53 ± 0.49. The pain score decreased from 2.87 ± 1.67 before operation to 1.07 ± 1.18 after operation, and the differences were statistically significant (p< 0.05). No severe complications occurred.ConclusionsCT-guided iodine-125 brachytherapy provided a safe and effective choice for recurrent BC with significant local therapeutic effects and minor complications, especially for elderly patients with chronic underlying disease and those who were not eligible for surgical resection and had failed to benefit from systemic therapy. |
| first_indexed | 2024-03-12T14:24:46Z |
| format | Article |
| id | doaj.art-dd4b5366822b44bd96bdec95075d4568 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T14:24:46Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-dd4b5366822b44bd96bdec95075d45682023-08-18T11:11:36ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.11718131171813CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancerJuan Wang0Xiaojing Chang1Ke Xu2Yansong Liang3Jinxin Zhao4Zezhou Liu5Hongtao Zhang6Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, ChinaDepartment of Radiotherapy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, ChinaDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, ChinaDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, ChinaDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, ChinaDepartment of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, ChinaBackgroundThe treatment of local–regional recurrent breast cancer (BC) after external beam radiotherapy is challenging. We aim to evaluate the effectiveness and safety of computed tomography (CT)–guided percutaneous iodine-125 brachytherapy for local recurrent BC.MethodsWe retrospectively analyzed 15 patients with local recurrent BC treated with CT-guided interstitial implantation of iodine-125 seeds. Regular contrast-enhanced CT was conducted to evaluate the tumor response. Follow-up survival, quality of life, and adverse events were analyzed.ResultsAmong the 15 patients, five were elderly patients (older than 80 years) and six were complicated with chronic underlying diseases. The median number of 125I seeds implantation was 33 (range: 20–130) with median dose 90 (D90, the minimum dose covering 90% of the target volume) of 108 Gy (range: 60–120 Gy). There was no significant difference in D90, V100 (the volume of the target receiving 100% of the prescription dose), and V150 (the volume of the target receiving 150% of the prescription dose) before and after operation (p > 0.05). The median follow-up was 14 months (range: 6–18 months). Six months after operation, the ORR was 66.7% (10/15) and the LCR was 93.3% (14/15). The 6- and 12-month survival rates were 100 and 41.6%, respectively, and the median survival time was 12.5 months. PS score decreased from 1.53 ± 0.81 to 0.53 ± 0.49. The pain score decreased from 2.87 ± 1.67 before operation to 1.07 ± 1.18 after operation, and the differences were statistically significant (p< 0.05). No severe complications occurred.ConclusionsCT-guided iodine-125 brachytherapy provided a safe and effective choice for recurrent BC with significant local therapeutic effects and minor complications, especially for elderly patients with chronic underlying disease and those who were not eligible for surgical resection and had failed to benefit from systemic therapy.https://www.frontiersin.org/articles/10.3389/fonc.2023.1171813/fulliodine-125 seedbrachytherapycomputed tomography guidancebreast cancersalvage therapyrecurrence |
| spellingShingle | Juan Wang Xiaojing Chang Ke Xu Yansong Liang Jinxin Zhao Zezhou Liu Hongtao Zhang CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer Frontiers in Oncology iodine-125 seed brachytherapy computed tomography guidance breast cancer salvage therapy recurrence |
| title | CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer |
| title_full | CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer |
| title_fullStr | CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer |
| title_full_unstemmed | CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer |
| title_short | CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer |
| title_sort | ct guided iodine 125 brachytherapy as salvage therapy for local regional recurrent breast cancer |
| topic | iodine-125 seed brachytherapy computed tomography guidance breast cancer salvage therapy recurrence |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1171813/full |
| work_keys_str_mv | AT juanwang ctguidediodine125brachytherapyassalvagetherapyforlocalregionalrecurrentbreastcancer AT xiaojingchang ctguidediodine125brachytherapyassalvagetherapyforlocalregionalrecurrentbreastcancer AT kexu ctguidediodine125brachytherapyassalvagetherapyforlocalregionalrecurrentbreastcancer AT yansongliang ctguidediodine125brachytherapyassalvagetherapyforlocalregionalrecurrentbreastcancer AT jinxinzhao ctguidediodine125brachytherapyassalvagetherapyforlocalregionalrecurrentbreastcancer AT zezhouliu ctguidediodine125brachytherapyassalvagetherapyforlocalregionalrecurrentbreastcancer AT hongtaozhang ctguidediodine125brachytherapyassalvagetherapyforlocalregionalrecurrentbreastcancer |